Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 95 (2), 405-411

Long-term Outcome of Kidney Transplantation in AL Amyloidosis

Affiliations

Long-term Outcome of Kidney Transplantation in AL Amyloidosis

Avital Angel-Korman et al. Kidney Int.

Abstract

Therapies for AL amyloidosis have dramatically improved, leading to longer patient survival; however, more AL amyloidosis patients are reaching end-stage renal disease (ESRD). There are no clear guidelines regarding eligibility for kidney transplantation in patients with AL amyloidosis, and data on outcomes are limited. We evaluated the clinical and laboratory data of 49 patients who were followed in the Amyloidosis Center at Boston University and underwent kidney transplantation at a center in the United States between 1987-2017. During a median follow-up of 7.2 years (range 0-19), the median patient survival from diagnosis was 15.4 years, and from kidney transplantation was 10.5 years. One, three, and five-year graft survival were 94%, 89%, and 81%, respectively. Patients with hematologic complete response or very good partial response prior to kidney transplantation had significantly better patient survival than patients with partial response or no response, and the median time to graft loss was 10.4 years versus 5.5 years, respectively. This is the largest published series of kidney transplantation in patients with AL amyloidosis, suggesting that kidney transplantation can have a good outcome in carefully selected patients, particularly in those who have achieved a complete response or very good partial response at the time of kidney transplantation.

Keywords: AL amyloidosis; ESRD; graft survival; hematologic response; renal transplantation.

Comment in

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

Publication types

MeSH terms

LinkOut - more resources

Feedback